Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MP 0250

Drug Profile

MP 0250

Alternative Names: MP0250

Latest Information Update: 15 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Molecular Partners AG
  • Class Antineoplastics; Proteins; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Hepatocyte growth factor inhibitors; Immunomodulators; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Multiple myeloma
  • Phase I/II Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 09 May 2019 Molecular Partners plans a phase II trial for Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA in 2019
  • 09 May 2019 Molecular Partners AG put hold on patients recruitment in a phase I/II trial in EGFR-mutated Non-small cell lung cancer due to kidney related adverse events
  • 06 Dec 2018 Molecular Partners AG plans a phase II trial for Multiple myeloma (Combination therapy, Second line therapy or greater, Refractory-metastatic disease)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top